
TY  - JOUR
TI  - Abstracts
JO  - European Journal of Heart Failure
JA  - Eur J Heart Fail
VL  - 19
IS  - S1
SN  - 1388-9842
UR  - https://doi.org/10.1002/ejhf.833
DO  - doi:10.1002/ejhf.833
SP  - 5
EP  - 601
PY  - 2017
ER  - 

TY  - JOUR
TI  - Poster Sessions
JO  - The FEBS Journal
JA  - FEBS J
VL  - 282
IS  - S1
SN  - 1742-464X
UR  - https://doi.org/10.1111/febs.13339
DO  - doi:10.1111/febs.13339
SP  - 55
EP  - 422
PY  - 2015
ER  - 

TY  - JOUR
TI  - Lymphocyte activation
JO  - Journal of Cellular Biochemistry
JA  - J. Cell. Biochem.
VL  - 56
IS  - S18D
SN  - 0730-2312
UR  - https://doi.org/10.1002/jcb.240560809
DO  - doi:10.1002/jcb.240560809
SP  - 283
EP  - 460
PY  - 1994
ER  - 

TY  - JOUR
TI  - Poster Sessions
JO  - European Journal of Immunology
JA  - Eur. J. Immunol.
VL  - 39
IS  - S1
SN  - 0014-2980
UR  - https://doi.org/10.1002/eji.200990224
DO  - doi:10.1002/eji.200990224
SP  - S55
EP  - S279
PY  - 2009
AB  - Abstract No Abtract
ER  - 

TY  - JOUR
TI  - Poster Tours
JO  - Pediatric Diabetes
JA  - Pediatr Diabetes
VL  - 17
IS  - S24
SN  - 1399-543X
UR  - https://doi.org/10.1111/pedi.12451
DO  - doi:10.1111/pedi.12451
SP  - 36
EP  - 164
PY  - 2016
ER  - 

TY  - JOUR
TI  - Plenary Lectures and Plenary Debate
JO  - International Journal of Andrology
VL  - 28
IS  - s1
SN  - 0105-6263
UR  - https://doi.org/10.1111/j.1365-2605.2005.00551_1.x
DO  - doi:10.1111/j.1365-2605.2005.00551_1.x
SP  - 1
EP  - 3
PY  - 2005
ER  - 

TY  - JOUR
TI  - ELECTROCARDIOGRAPHY, BIOLOGICAL SENSORS, ABLATION AND ANTIARRHYTHMIC DRUGS
JO  - Pacing and Clinical Electrophysiology
VL  - 12
IS  - 7
SN  - 0147-8389
UR  - https://doi.org/10.1111/j.1540-8159.1989.tb01993.x
DO  - doi:10.1111/j.1540-8159.1989.tb01993.x
SP  - 1283
EP  - 1301
PY  - 1989
ER  - 

AU  - Fricker, Simon P.
C7  - pp. 1-20
TI  - Nitrogen Monoxide (Nitric Oxide): Bioinorganic Chemistry
UR  - https://doi.org/10.1002/9781119951438.eibc2724
DO  - doi:10.1002/9781119951438.eibc2724
SP  - 1-20
KW  - nitrogen monoxide
KW  - nitric oxide
KW  - nitric oxide synthase
KW  - peroxynitrite
KW  - nitrosothiol
KW  - soluble guanylate cyclase
KW  - phosphodiesterase 5
KW  - hemoglobin
PY  - 1989
AB  - Abstract The discovery of nitrogen monoxide (nitric oxide, NO) as the vasodilator molecule endothelium-derived relaxing factor revealed a major physiological role for this simple diatomic molecule. We now know that NO regulates cardiovascular function, is a neurotransmitter, and is a component of the innate immune response to infection and cancer. The physiological effects of NO are mediated by its varied chemistry which includes redox chemistry and interaction with transition metals. NO can interact with iron-heme-containing proteins including hemoglobin and cytochrome c oxidase, and nonheme iron proteins such as aconitase and bacterial transcription regulatory proteins. NO reacts with superoxide to form the highly reactive peroxynitrite which decomposes to give the hydroxyl radical. Nitrosothiols, thiol adducts of NO, act to control NO release, and to shuttle NO between proteins and transport NO across cell membranes. NO is produced by one of three nitric oxide synthase (NOS) enzymes, endothelial NOS, neuronal NOS, and inducible NOS. Signaling functions are mediated via interaction with the heme-containing protein soluble guanylate cyclase (GC), which produces the cell signaling molecule cyclic guanosine monophosphate (cGMP). This, in turn, is hydrolyzed by phosphodiesterase 5 (PDE5), which turns off NO signaling. Perturbation in NO function contributes to the pathophysiology of many disease states. Endothelial dysfunction and subsequent reduced NO production contribute to hypertension and atherosclerosis. Excess NO is a mediator of inflammatory disease, and neurodegenerative disease, due in part to the production of peroxynitrite. The cardiovascular collapse observed in septic shock is caused by the vasodilator action of NO. Targeting the NO pathway theoretically provides many opportunities for therapeutic intervention. The NO donor drugs glyceryl trinitrate, isosorbide mononitrate, isosorbide dinitrate, and amyl nitrate are used to treat acute angina; and inhaled NO is used to treat persistent pulmonary hypertension in new born infants. Conversely, NOS inhibitors and NO scavengers have been explored to counteract NO as a mediator of disease. Though promising results have been obtained in animal models of disease these latter approaches have had little clinical success. However, targeting downstream of NO has been more successful with new clinically approved classes of drugs such as the inhibitors of PDE5 sildenafil, tadalafil, and vardenafil; and the stimulator of the NO receptor soluble GC, riociguat. It has become apparent that the biological actions, and biological chemistry, of NO are very complex. New opportunities for drug discovery could result from an improved understanding of the biology of NO.
ER  - 

TY  - JOUR
TI  - American College of Veterinary Internal Medicine
JO  - Journal of Veterinary Internal Medicine
VL  - 18
IS  - 3
UR  - https://doi.org/10.1111/j.1939-1676.2004.tb02565.x
DO  - doi:10.1111/j.1939-1676.2004.tb02565.x
SP  - 375
EP  - 460
PY  - 2004
ER  - 

TY  - JOUR
TI  - The Japanese Society of Neuropathology
JO  - Neuropathology
VL  - 28
IS  - 2
UR  - https://doi.org/10.1111/j.1440-1789.2008.00917.x
DO  - doi:10.1111/j.1440-1789.2008.00917.x
SP  - 177
EP  - 226
PY  - 2008
AB  - Abstracts of the 49th Annual Meeting May 20?22, 2008 Tower Hall Funabori, Tokyo President: Atsuo Koto, MD Vice President: Norihiro Suzuki, MD Plenary and Symposia (S): Main Hall Platform Presentation (O-A): Main Hall Platform Presentation (O-B): Banquette Room ?Zuiun? Poster Presentaion (P-C, D, E): Exhibition Hall I: 1st day (May 20), II: 2nd day (May 21), III: 3rd day (May 22)
ER  - 

TY  - JOUR
TI  - Workshops
JO  - International Journal of Andrology
VL  - 28
IS  - s1
UR  - https://doi.org/10.1111/j.1365-2605.2005.00551_2.x
DO  - doi:10.1111/j.1365-2605.2005.00551_2.x
SP  - 4
EP  - 9
PY  - 2005
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - International Journal of Andrology
VL  - 28
IS  - s1
UR  - https://doi.org/10.1111/j.1365-2605.2005.00551_5.x
DO  - doi:10.1111/j.1365-2605.2005.00551_5.x
SP  - 45
EP  - 129
PY  - 2005
ER  - 

TY  - JOUR
TI  - Seoul Satellite Symposium
JO  - International Journal of Andrology
VL  - 28
IS  - s1
UR  - https://doi.org/10.1111/j.1365-2605.2005.00551_7.x
DO  - doi:10.1111/j.1365-2605.2005.00551_7.x
SP  - 132
EP  - 133
PY  - 2005
ER  - 

TY  - JOUR
TI  - Free Communications
JO  - International Journal of Andrology
VL  - 28
IS  - s1
UR  - https://doi.org/10.1111/j.1365-2605.2005.00551_4.x
DO  - doi:10.1111/j.1365-2605.2005.00551_4.x
SP  - 25
EP  - 44
PY  - 2005
ER  - 

TY  - JOUR
TI  - Symposia
JO  - International Journal of Andrology
VL  - 28
IS  - s1
UR  - https://doi.org/10.1111/j.1365-2605.2005.00551_3.x
DO  - doi:10.1111/j.1365-2605.2005.00551_3.x
SP  - 10
EP  - 24
PY  - 2005
ER  - 

TY  - JOUR
TI  - Video Presentations
JO  - International Journal of Andrology
VL  - 28
IS  - s1
UR  - https://doi.org/10.1111/j.1365-2605.2005.00551_6.x
DO  - doi:10.1111/j.1365-2605.2005.00551_6.x
SP  - 130
EP  - 131
PY  - 2005
ER  - 

TY  - JOUR
TI  - Abstracts-part III (Continue in Part IV)
JO  - Proceedings of the International Society for Magnetic Resonance in Medicine
JA  - Proc. Soc. Magn. Reson. Med.
VL  - 1992
IS  - S2
UR  - https://doi.org/10.1002/mrmp.22419920205
DO  - doi:10.1002/mrmp.22419920205
SP  - 2725
EP  - 2911
PY  - 1992
ER  - 

C7  - pp. 75-99
TI  - Phase I Enzyme Inhibition
SN  - 9780470863527
UR  - https://doi.org/10.1002/0470032669.ch5
DO  - doi:10.1002/0470032669.ch5
SP  - 75-99
KW  - dosage and clearance
KW  - ‘polypharmacy’
KW  - CYP isoform
KW  - Phase I Enzyme Inhibition
KW  - competitive inhibition
KW  - Non-competitive inhibition
KW  - Seratonin reuptake inhibitors (SSRIs)
KW  - Efflux transporter systems
KW  - Torsades des Pointes
KW  - Muscle damage (rhabdomyolysis)
PY  - 1992
AB  - Summary This chapter contains sections titled: Introduction Inhibition of metabolism ? general aspects Mechanisms of inhibition Cell transport systems and CYP3A inhibitors Clinical consequences of drug inhibition Use of inhibitors for positive clinical intervention
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Acta Anaesthesiologica Scandinavica
VL  - 33
IS  - s91
SN  - 9780470863527
UR  - https://doi.org/10.1111/j.1399-6576.1989.tb03031.x
DO  - doi:10.1111/j.1399-6576.1989.tb03031.x
SP  - 8
EP  - 158
PY  - 1989
ER  - 

TY  - JOUR
TI  - AASLD Abstracts
JO  - Hepatology
JA  - Hepatology
VL  - 58
IS  - S1
SN  - 9780470863527
UR  - https://doi.org/10.1002/hep.26727
DO  - doi:10.1002/hep.26727
SP  - 208A
EP  - 1309A
PY  - 2013
ER  - 
